SCHEDULE: Armistice Capital Discloses 4.99% Stake in CNS Pharma
Beneficial Ownership Disclosure
Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in CNS Pharmaceuticals Inc. common stock.
Summary
- Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 30,177 shares of CNS Pharmaceuticals Inc. common stock.
- This ownership represents 4.99% of the company's outstanding common stock.
- The shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital, LLC exercising shared voting and dispositive power.
- Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these securities.
- The reporting persons certified that the securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of the issuer.
- The date of the event requiring this filing was September 30, 2025, and the filing was signed on November 14, 2025.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual disclosure of beneficial ownership, providing transparency without indicating positive or negative operational or financial performance.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
This filing is a standard disclosure of beneficial ownership by an investment firm, providing transparency regarding significant holdings in a publicly traded company. It does not inherently reflect broader industry trends but rather a specific investment position.
Related Party Transactions
- Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares. Steven Boyd is the managing member of Armistice Capital, LLC. This structure defines the beneficial ownership and control over the reported securities.
Stakeholder Impact
- Shareholders are informed of a significant institutional investor's stake, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which requires the filing of this statement, indicating the point at which the beneficial ownership percentage was determined. |
| 11/14/2025 | Date the Schedule 13G Amendment No. 1 was signed by Armistice Capital, LLC and Steven Boyd. |
Keywords
CNS Pharmaceuticals Inc., Armistice Capital, Steven Boyd, Beneficial Ownership, Schedule 13G, Common Stock, Investment Management, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.